Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41

Journal of Biomolecular Screening

Volumn 8, Issue 6, 2003, Pages 685-693

  Liu, Shuwen ^a   Boyer Chatenet, Louise ^a   Lu, Hong ^a   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

FLISA; Fusion inhibitors; Gp41; HIV 1; HTS

Indexed keywords

ADS J1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FLUORESCEIN ISOTHIOCYANATE; FORMAZAN; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NC 1; PEPTIDE C34; PEPTIDE DERIVATIVE; PEPTIDE N36; SAQUINAVIR; T 22; UNCLASSIFIED DRUG; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MECHANISM; FLUORESCENCE; FLUORESCENCE LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; METABOLISM; METHODOLOGY; ROBOTICS; SENSITIVITY AND SPECIFICITY; TEMPERATURE; TIME;

DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENCE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; IMMUNOSORBENT TECHNIQUES; PEPTIDE FRAGMENTS; ROBOTICS; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY; TEMPERATURE; TIME FACTORS;

EID: 0347689876     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057103259155     Document Type: Article

References (35)

1. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998;93:681-684.
2. Moore JP, Dragic T: HIV. See a pocket, block it. Nature 1999;401:759.
3. LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM: HIV fusion and its inhibition. Antiviral Res 2001;50:95-115.
4. Lu M, Blacklow SC, Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-1082.
5. Sattentau QJ, Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
6. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
7. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810.
8. Chan DC, Pass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
9. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-428.
10. Tan K, Liu J, Wang J, Shen S, Liu M: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997;94:12303-12308.
11. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-10541.
12. Jiang S, Lin K, Strick N, Neurath AR: HIV-1 inhibition by a peptide. Nature 1993;365:113.
13. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91:9770-9774.
14. Jiang S, Zhao Q, Debnath AK: Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002;8:563-580.
15. Chen RY, Kilby JM, Saag MS: Enfuvirtide. Expert Opin Investig Drugs 2002;11:1837-1843.
16. Lalezari JP, Henry K, O'Hearn M, et al: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
17. Lalezari JP, Eron JJ, Carlson M, et al: A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-698.
18. Lu M, Kim PS: A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997;15:465-471.
19. Jiang S, Lin K, Zhang L, Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999;80:85-96.
20. Jiang S, Lin K, Lu M: A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 1998;72:10213-10217.
21. Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S: XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 2002;18:989-997.
22. Jiang S, Lin K, Neurath AR: Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med 1991;174:1557-1563.
23. Jiang S, Radigan L, Zhang L: A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc SPIE 2000;3926:212-219.
24. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
25. Macarron R, Hertzberg RP: Design and implementation of high throughput screening assays. In Janzen WP (ed): High Throughput Screening: Method and Protocols. Totowa, NJ: Humanan, 2002:1-29.
26. Oldenburg KR, Kariv I, Zhang J, Chung TDY, Lin S: Assay miniaturization: developing technologies and assay formats. In Seethala R, Fernandes PB (eds): Handbook of Drug Screening. New York: Marcel Dekker, 2001;525-562.
27. Debnath AK: A "fragment fitting" approach to model disulfide loops by utilizing homologous peptide fragments from unrelated proteins of known structures: application to the V3 loop of the HIV-1 envelope glycoprotein gp120. J Mol Modeling 1997;3:31-47.
28. Debnath AK, Radigan L, Jiang S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 1999;42:3203-3209.
29. Murakami T, Zhang TY, Koyanagi Y, et al: Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999;73:7489-7496.
30. Deen KC, McDougal JS, Inacker R, et al: A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988;331:82-84.
31. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ: Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987;238:1704-1707.
32. Okumura N, Aosai F, Yui K, et al: Cellular FITC-linked immunospecific assay (cell-FLISA) for detection of monoclonal antibodies against cell-surface antigens. Hum Immunol 1986;15:97-108.
33. Swartzman EE, Miraglia SJ, Mellentin-Michelotti J, Evangelista L, Yuan PM: A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. Anal Biochem 1999;271:143-151.
34. Oelschlaeger P, Srikant-Iyer S, Lange S, Schmitt J, Schmid R: Fluorophor-linked immunosorbent assay: a time- and cost-saving method for the characterization of antibody fragments using a fusion protein of a single-chain antibody fragment and enhanced green fluorescent protein. Anal Biochem 2002;309:27-34.
35. Komatsu N, Shichijo S, Maeda Y, Itoh K: Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system. J Immunol Method's 2002;263:169-176.